acetic acid 5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl ester

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: acetic acid 5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl ester
• 英文别名: [5-(1-Benzylindazol-3-yl)furan-2-yl]methyl acetate
• 化学式: C₂₁H₁₈N₂O₃
• 分子量: 346.386
• InChiKey: DEMUCGPGQHZRLK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  57.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1-苄基-3-(5-甲酰基呋喃-2-基)吲唑 在 4-二甲氨基吡啶 、 sodium tetrahydroborate 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 生成 acetic acid 5-(1-benzyl-1H-indazol-3-yl)-furan-2-ylmethyl ester
  参考文献：
  名称：

  Design, synthesis and insight into the structure–activity relationship of 1,3-disubstituted indazoles as novel HIF-1 inhibitors

  摘要：

  Design, synthesis and insight into the structure-activity relationship (SAR) of 1,3-disubstituted indazoles as novel HIF-1 inhibitors are described. In particular, the substituted furan moiety on indazole skeleton as well as its substitution pattern turns out crucial for the high HIF-1 inhibition. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.08.120

文献信息

• Blockade of voltage dependent sodium channels
  申请人：——

  公开号：US20030171403A1

  公开（公告）日：2003-09-11

  Compounds of formula (1), and pharmaceutically acceptable salts thereof, are capable of blockading voltage-dependent sodium channels and are useful in particular, in treating glaucoma and multiple sclerosis.

  式（1）的化合物及其药学上可接受的盐能够阻断电压依赖性钠通道，并且在治疗青光眼和多发性硬化症方面具有用处。
• Fused pyrazolyls as anti-cancer drugs
  申请人：Yung Shin Pharm. Ind. Co. Ltd.

  公开号：EP1586572A1

  公开（公告）日：2005-10-19

  A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical composition containing an effective amount of the above-described fused pyrazolyl compound.

  下式的融合吡唑化合物： 其中 A、Ar1、Ar2、R1、R2、R3 和 R4 如本文所定义。还公开了一种药物组合物，其中含有有效量的上述融合吡唑化合物。
• Novel Pyrazole Derivatives Effectively Inhibit Osteoclastogenesis, a Potential Target for Treating Osteoporosis
  作者：Ting-Hao Kuo、Tzu-Hung Lin、Rong-Sen Yang、Sheng-Chu Kuo、Wen-Mei Fu、Hsin-Yi Hung

  DOI：10.1021/jm502014h

  日期：2015.6.25

  As human beings live longer, age-related diseases such as osteoporosis will become more prevalent. Intolerant side effects and poor responses to current treatments are observed. Therefore, novel effective therapeutic agents are greatly needed. Here, pyrazole derivatives were designed and synthesized, and their osteoclastogenesis inhibitory effects both in vitro and in vivo were evaluated. The most promising compound 13 with a 2-(dimethylamino)ethyl group inhibited markedly in vitro osteoclastogenesis as well as the bone resorption activity of osteoclasts. Compound 13 affected osteoclast's early proliferation and differentiation more than later fusion and maturation stages. In ovariectomized (OVX) mice, compound 13 can inhibit the loss of trabecular bone volume, trabecular bone number, and trabecular thickness. Moreover, compound 13 can antagonize OVX-induced reduction of serum bone resorption marker and then compensatory increase of the bone formation marker. To sum up, compound 13 has high potential to be developed into a novel therapeutic agent for treating osteoporosis in the future.
• US7009056B2
  申请人：——

  公开号：US7009056B2

  公开（公告）日：2006-03-07
• US7790761B2
  申请人：——

  公开号：US7790761B2

  公开（公告）日：2010-09-07